



## **Crescendo Biologics' Brian McGuinness to Present at IBC Antibody Engineering & Therapeutics Conference 13 December 2017**

**Cambridge, UK, 8 December 2017** – Crescendo Biologics Limited (Crescendo), the drug developer of Humabody® therapeutics, announces that Dr Brian McGuinness, Head of New Product and Business Development, will be presenting at the Antibody Engineering & Therapeutics Conference in San Diego, USA on 13 December 2017.

The Antibody Engineering & Therapeutics Conference, organised by IBC Life Sciences, is being held in San Diego from 11 – 15 December. Brian McGuinness will present a talk on '*Multifunctional Biologics for Targeted Therapy: From Toxins to T-cells*', within the Antibody-Drug Conjugates & Fusion Proteins track. This will cover the beneficial characteristics of Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies. This will replace the previously scheduled talk entitled '*Small is Beautiful – Humabody® Drug Conjugates, HDCs a Real Alternative to ADCs*'.

**Title:** Multifunctional Biologics for Targeted Therapy: From Toxins to T-cells

**Date:** Wednesday 13 December 2017

**Time:** 11.00

**Location:** Manchester Grand Hyatt San Diego, 1 Market Place, San Diego, CA 92101, USA

For more information on Crescendo's presentation or for media enquiries, please contact [crescendo@instinctif.com](mailto:crescendo@instinctif.com).

**Ends**

**For more information, please contact:**

<b>Crescendo Biologics</b> <b>Dr Peter Pack, CEO</b>	<b>Tel:44 (0)1223 497140</b> <b>info@crescendobiologics.com</b>
<b>Instinctif Partners</b> <b>Dr Christelle Kerouedan / Melanie Toyne-Sewell</b>	<b>Tel:44 (0)20 7457 2020</b> <b>crescendo@instinctif.com</b>

### **Notes to Editors:**

#### **About Crescendo Biologics Ltd**

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody® therapeutics in oncology with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.



The Company's Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V<sub>H</sub> domain building blocks (Humabody® V<sub>H</sub>) comprising the full structural diversity of the human V<sub>H</sub> repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com)